Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | Executive Vice President | February 26, 2010 | March 02, 2010 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date February 26, 2010 · Filed March 02, 2010
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 110,509 |
Ending reported balance
After 2010-02-26 transaction · row 13
13 source rows · reconciled sequenceRow 1 · 2010-02-26 · Grant · Acquired 26,667 · Balance 123,843 F1: Settlement of a performance-based restricted stock unit in shares in a transaction exempt from Section 16(b) under Rule 16b-3. Row 2 · 2010-02-26 · Sale · Disposed 3,634 · Balance 120,209 Row 3 · 2010-02-26 · Sale · Disposed 100 · Balance 120,109 Row 4 · 2010-02-26 · Sale · Disposed 400 · Balance 119,709 Row 5 · 2010-02-26 · Sale · Disposed 1,200 · Balance 118,509 Row 6 · 2010-02-26 · Sale · Disposed 3,500 · Balance 115,009 Row 7 · 2010-02-26 · Sale · Disposed 300 · Balance 114,709 Row 8 · 2010-02-26 · Sale · Disposed 100 · Balance 114,609 Row 9 · 2010-02-26 · Sale · Disposed 1,100 · Balance 113,509 Row 10 · 2010-02-26 · Sale · Disposed 100 · Balance 113,409 Row 11 · 2010-02-26 · Sale · Disposed 100 · Balance 113,309 Row 12 · 2010-02-26 · Sale · Disposed 2,600 · Balance 110,709 Row 13 · 2010-02-26 · Sale · Disposed 200 · Balance 110,509 |
Filing footnotes · ownership attribution and instrument terms
F1: Settlement of a performance-based restricted stock unit in shares in a transaction exempt from Section 16(b) under Rule 16b-3.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 26, 2010 Filed Mar 2, 2010 23:52 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 200 | $54.33 | $10,866.26 |
DisclosureSEC source: 0001179110-10-004240 · edgar.xml · nonDerivative · entry 13 Bohuon Olivier · CIK 0001360215 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,509 Read SEC document |
| February 26, 2010 Filed Mar 2, 2010 23:52 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,600 | $54.33 | $141,260.60 |
DisclosureSEC source: 0001179110-10-004240 · edgar.xml · nonDerivative · entry 12 Bohuon Olivier · CIK 0001360215 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,709 Read SEC document |
| February 26, 2010 Filed Mar 2, 2010 23:52 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $54.33 | $5,433.09 |
DisclosureSEC source: 0001179110-10-004240 · edgar.xml · nonDerivative · entry 11 Bohuon Olivier · CIK 0001360215 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,309 Read SEC document |
| February 26, 2010 Filed Mar 2, 2010 23:52 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $54.33 | $5,433.08 |
DisclosureSEC source: 0001179110-10-004240 · edgar.xml · nonDerivative · entry 10 Bohuon Olivier · CIK 0001360215 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,409 Read SEC document |
| February 26, 2010 Filed Mar 2, 2010 23:52 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,100 | $54.33 | $59,763.77 |
DisclosureSEC source: 0001179110-10-004240 · edgar.xml · nonDerivative · entry 9 Bohuon Olivier · CIK 0001360215 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,509 Read SEC document |
| February 26, 2010 Filed Mar 2, 2010 23:52 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $54.33 | $5,433.06 |
DisclosureSEC source: 0001179110-10-004240 · edgar.xml · nonDerivative · entry 8 Bohuon Olivier · CIK 0001360215 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,609 Read SEC document |
| February 26, 2010 Filed Mar 2, 2010 23:52 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 300 | $54.33 | $16,299.06 |
DisclosureSEC source: 0001179110-10-004240 · edgar.xml · nonDerivative · entry 7 Bohuon Olivier · CIK 0001360215 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,709 Read SEC document |
| February 26, 2010 Filed Mar 2, 2010 23:52 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 3,500 | $54.33 | $190,155.00 |
DisclosureSEC source: 0001179110-10-004240 · edgar.xml · nonDerivative · entry 6 Bohuon Olivier · CIK 0001360215 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,009 Read SEC document |
| February 26, 2010 Filed Mar 2, 2010 23:52 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,200 | $54.32 | $65,185.20 |
DisclosureSEC source: 0001179110-10-004240 · edgar.xml · nonDerivative · entry 5 Bohuon Olivier · CIK 0001360215 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,509 Read SEC document |
| February 26, 2010 Filed Mar 2, 2010 23:52 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 400 | $54.32 | $21,728.20 |
DisclosureSEC source: 0001179110-10-004240 · edgar.xml · nonDerivative · entry 4 Bohuon Olivier · CIK 0001360215 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,709 Read SEC document |
| February 26, 2010 Filed Mar 2, 2010 23:52 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $54.32 | $5,432.04 |
DisclosureSEC source: 0001179110-10-004240 · edgar.xml · nonDerivative · entry 3 Bohuon Olivier · CIK 0001360215 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,109 Read SEC document |
| February 26, 2010 Filed Mar 2, 2010 23:52 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 3,634 | $54.32 | $197,398.88 |
DisclosureSEC source: 0001179110-10-004240 · edgar.xml · nonDerivative · entry 2 Bohuon Olivier · CIK 0001360215 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,209 Read SEC document |
| February 26, 2010 Filed Mar 2, 2010 23:52 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 26,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-10-004240 · edgar.xml · nonDerivative · entry 1 Bohuon Olivier · CIK 0001360215 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,843 F1 · shares: Settlement of a performance-based restricted stock unit in shares in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| February 19, 2010 Filed Feb 24, 2010 01:51 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 46,900 | $0.00 Strike: $54.50 | $0.00 |
DisclosureSEC source: 0001179110-10-003599 · edgar.xml · derivative · entry 2 Bohuon Olivier · CIK 0001360215 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,900 Underlying: Common shares · 46,900 shares Expires 2020-02-18 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 15,634 on 02/19/2011, 15,633 on 02/19/2012, and 15,633 on 02/19/2013. Read SEC document |
| February 19, 2010 Filed Feb 24, 2010 01:51 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 32,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-10-003599 · edgar.xml · nonDerivative · entry 1 Bohuon Olivier · CIK 0001360215 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,176 F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2009 Incentive Stock Program. The units generally vest on the third anniversary of their grant date and include the right to have stock withheld for tax purposes. Each unit represents the contingent right to receive one Abbott common share. Read SEC document |
| February 16, 2010 Filed Feb 18, 2010 23:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 6,100 | $54.39 | $331,785.10 |
DisclosureSEC source: 0001179110-10-003133 · edgar.xml · nonDerivative · entry 4 Bohuon Olivier · CIK 0001360215 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,176 Read SEC document |
| February 16, 2010 Filed Feb 18, 2010 23:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $54.39 | $5,439.02 |
DisclosureSEC source: 0001179110-10-003133 · edgar.xml · nonDerivative · entry 3 Bohuon Olivier · CIK 0001360215 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,276 Read SEC document |
| February 16, 2010 Filed Feb 18, 2010 23:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,300 | $54.39 | $125,101.60 |
DisclosureSEC source: 0001179110-10-003133 · edgar.xml · nonDerivative · entry 2 Bohuon Olivier · CIK 0001360215 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,376 Read SEC document |
| February 16, 2010 Filed Feb 18, 2010 23:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 17,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-10-003133 · edgar.xml · nonDerivative · entry 1 Bohuon Olivier · CIK 0001360215 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,676 F1 · shares: Settlement of a performance-based restricted stock unit in shares in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| February 16, 2010 Filed Feb 24, 2010 01:45 UTC Amendment | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 6,100 | $54.39 | $331,785.10 |
DisclosureSEC source: 0001179110-10-003583 · edgar.xml · nonDerivative · entry 3 Bohuon Olivier · CIK 0001360215 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,176 Read SEC document |
| February 16, 2010 Filed Feb 24, 2010 01:45 UTC Amendment | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $54.39 | $5,439.02 |
DisclosureSEC source: 0001179110-10-003583 · edgar.xml · nonDerivative · entry 2 Bohuon Olivier · CIK 0001360215 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,276 Read SEC document |
| February 16, 2010 Filed Feb 24, 2010 01:45 UTC Amendment | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,300 | $54.39 | $125,101.60 |
DisclosureSEC source: 0001179110-10-003583 · edgar.xml · nonDerivative · entry 1 Bohuon Olivier · CIK 0001360215 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,376 Read SEC document |
| November 12, 2009 Filed Nov 13, 2009 23:21 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 36,000 | $0.00 Strike: $44.16 | $0.00 |
DisclosureSEC source: 0001179110-09-015487 · edgar.xml · derivative · entry 16 Bohuon Olivier · CIK 0001360215 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 36,000 shares Expires 2016-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| November 12, 2009 Filed Nov 13, 2009 23:21 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 34,800 | $0.00 Strike: $46.34 | $0.00 |
DisclosureSEC source: 0001179110-09-015487 · edgar.xml · derivative · entry 15 Bohuon Olivier · CIK 0001360215 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 34,800 shares Expires 2015-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| November 12, 2009 Filed Nov 13, 2009 23:21 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $53.34 | $5,334.00 |
DisclosureSEC source: 0001179110-09-015487 · edgar.xml · nonDerivative · entry 14 Bohuon Olivier · CIK 0001360215 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,676 Read SEC document |
| November 12, 2009 Filed Nov 13, 2009 23:21 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,400 | $53.33 | $127,992.00 |
DisclosureSEC source: 0001179110-09-015487 · edgar.xml · nonDerivative · entry 13 Bohuon Olivier · CIK 0001360215 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,776 Read SEC document |
| November 12, 2009 Filed Nov 13, 2009 23:21 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,900 | $53.32 | $154,628.00 |
DisclosureSEC source: 0001179110-09-015487 · edgar.xml · nonDerivative · entry 12 Bohuon Olivier · CIK 0001360215 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,176 Read SEC document |
| November 12, 2009 Filed Nov 13, 2009 23:21 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 4,800 | $53.31 | $255,888.00 |
DisclosureSEC source: 0001179110-09-015487 · edgar.xml · nonDerivative · entry 11 Bohuon Olivier · CIK 0001360215 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,076 Read SEC document |
| November 12, 2009 Filed Nov 13, 2009 23:21 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 4,600 | $53.30 | $245,180.00 |
DisclosureSEC source: 0001179110-09-015487 · edgar.xml · nonDerivative · entry 10 Bohuon Olivier · CIK 0001360215 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,876 Read SEC document |
| November 12, 2009 Filed Nov 13, 2009 23:21 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 15,400 | $53.29 | $820,666.00 |
DisclosureSEC source: 0001179110-09-015487 · edgar.xml · nonDerivative · entry 9 Bohuon Olivier · CIK 0001360215 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,476 Read SEC document |
| November 12, 2009 Filed Nov 13, 2009 23:21 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 21,800 | $53.28 | $1,161,504.00 |
DisclosureSEC source: 0001179110-09-015487 · edgar.xml · nonDerivative · entry 8 Bohuon Olivier · CIK 0001360215 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,876 Read SEC document |
| November 12, 2009 Filed Nov 13, 2009 23:21 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 14,900 | $53.27 | $793,723.00 |
DisclosureSEC source: 0001179110-09-015487 · edgar.xml · nonDerivative · entry 7 Bohuon Olivier · CIK 0001360215 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,676 Read SEC document |
| November 12, 2009 Filed Nov 13, 2009 23:21 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 15,500 | $53.26 | $825,530.00 |
DisclosureSEC source: 0001179110-09-015487 · edgar.xml · nonDerivative · entry 6 Bohuon Olivier · CIK 0001360215 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,576 Read SEC document |
| November 12, 2009 Filed Nov 13, 2009 23:21 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 7,700 | $53.25 | $410,025.00 |
DisclosureSEC source: 0001179110-09-015487 · edgar.xml · nonDerivative · entry 5 Bohuon Olivier · CIK 0001360215 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,076 Read SEC document |
| November 12, 2009 Filed Nov 13, 2009 23:21 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 200 | $53.26 | $10,652.10 |
DisclosureSEC source: 0001179110-09-015487 · edgar.xml · nonDerivative · entry 4 Bohuon Olivier · CIK 0001360215 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,776 Read SEC document |
| November 12, 2009 Filed Nov 13, 2009 23:21 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 500 | $53.24 | $26,620.00 |
DisclosureSEC source: 0001179110-09-015487 · edgar.xml · nonDerivative · entry 3 Bohuon Olivier · CIK 0001360215 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,976 Read SEC document |
| November 12, 2009 Filed Nov 13, 2009 23:21 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 36,000 | $44.16 | $1,589,760.00 |
DisclosureSEC source: 0001179110-09-015487 · edgar.xml · nonDerivative · entry 2 Bohuon Olivier · CIK 0001360215 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,476 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 12, 2009 Filed Nov 13, 2009 23:21 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 34,800 | $46.34 | $1,612,632.00 |
DisclosureSEC source: 0001179110-09-015487 · edgar.xml · nonDerivative · entry 1 Bohuon Olivier · CIK 0001360215 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,476 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 01, 2009 Filed Aug 4, 2009 21:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 14,500 | $0.00 Strike: $45.48 | $0.00 |
DisclosureSEC source: 0001179110-09-011566 · edgar.xml · derivative · entry 1 Bohuon Olivier · CIK 0001360215 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,500 Underlying: Common shares · 14,500 shares Expires 2019-08-01 F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 4,834 on 8/01/2010, 4,833 on 8/01/2011, and 4,833 on 8/01/2012. Read SEC document |
| April 24, 2009 Filed Apr 28, 2009 22:20 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 4,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-09-026802 · a4.xml · nonDerivative · entry 1 Bohuon Olivier · CIK 0001360215 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,676 F1 · shares: Settlement of a performance-based restricted stock unit in shares in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| February 27, 2009 Filed Mar 3, 2009 19:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 14,834 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-09-013812 · a4.xml · nonDerivative · entry 1 Bohuon Olivier · CIK 0001360215 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,009 F1 · shares: Settlement of a performance-based restricted stock unit in shares in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| February 20, 2009 Filed Feb 24, 2009 22:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 50,400 | $0.00 Strike: $54.14 | $0.00 |
DisclosureSEC source: 0001104659-09-011810 · a4.xml · derivative · entry 1 Bohuon Olivier · CIK 0001360215 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,400 Underlying: Common shares · 50,400 shares Expires 2019-02-19 F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 16,800 on 2/20/2010, 16,800 on 2/20/11, and 16,800 on 2/20/12. Read SEC document |
| February 17, 2009 Filed Feb 19, 2009 17:17 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 4,167 | $54.94 | $228,934.98 |
DisclosureSEC source: 0001104659-09-010666 · a4.xml · nonDerivative · entry 1 Bohuon Olivier · CIK 0001360215 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,175 F1 · kind: Settlement of a performance-based restricted stock unit in shares in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| April 24, 2008 Filed Apr 28, 2008 23:22 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 4,666 | $50.56 | $235,912.96 |
DisclosureSEC source: 0001104659-08-027468 · a4.xml · nonDerivative · entry 1 Bohuon Olivier · CIK 0001360215 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,008 F1 · kind: Settlement of a performance-based restricted stock unit in shares in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| March 27, 2008 Filed Mar 28, 2008 21:00 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 26,311 | $0.00 Strike: $54.03 | $0.00 |
DisclosureSEC source: 0001104659-08-020811 · a4.xml · derivative · entry 4 Bohuon Olivier · CIK 0001360215 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,311 Underlying: Common shares · 26,311 shares Expires 2013-05-31 F1 · security: Employee stock option, including replacement option feature granted pursuant to Abbott Laboratories Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| March 27, 2008 Filed Mar 28, 2008 21:00 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 34,023 | $0.00 Strike: $41.78 | $0.00 |
DisclosureSEC source: 0001104659-08-020811 · a4.xml · derivative · entry 3 Bohuon Olivier · CIK 0001360215 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 34,023 shares Expires 2013-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option, including replacement option feature granted pursuant to Abbott Laboratories Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| March 27, 2008 Filed Mar 28, 2008 21:00 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 26,311 | $54.03 | $1,421,583.33 |
DisclosureSEC source: 0001104659-08-020811 · a4.xml · nonDerivative · entry 2 Bohuon Olivier · CIK 0001360215 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,342 Read SEC document |
| March 27, 2008 Filed Mar 28, 2008 21:00 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 34,023 | $41.78 | $1,421,603.42 |
DisclosureSEC source: 0001104659-08-020811 · a4.xml · nonDerivative · entry 1 Bohuon Olivier · CIK 0001360215 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,653 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 29, 2008 Filed Mar 5, 2008 01:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 6,800 | $54.22 | $368,696.00 |
DisclosureSEC source: 0001104659-08-015206 · a4.xml · nonDerivative · entry 1 Bohuon Olivier · CIK 0001360215 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,630 F1 · kind: Settlement of a performance-based restricted stock unit in shares in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| February 17, 2008 Filed Feb 20, 2008 23:30 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 4,166 | $55.55 | $231,421.30 |
DisclosureSEC source: 0001104659-08-011835 · a4.xml · nonDerivative · entry 1 Bohuon Olivier · CIK 0001360215 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,830 F1 · kind: Settlement of a performance-based restricted stock unit in shares in a transaction exempt from Section 16(b) under Rule 16b-3. F2 · balance_after: The amount of securities beneficially owned also includes the 17,000 restricted stock units awarded on 2/16/07 and timely reported on Table II of a Form 4 dated 2/21/2007 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.